Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Complete Response Rate at 450 Days 28.6% ?
View:
Post by Eoganacht on Oct 08, 2024 12:16pm

Complete Response Rate at 450 Days 28.6% ?

In the news release it says the 450 day CR rate is 26.5%

This rate represents the 18 out of 68 patients who are CR at 450 days.

But 5 of those 68 patients have not yet reached 450 days so isn't the current CR rate at 450 days actually more like 18 out of 63 patients or 28.6% ?
Comment by enriquesuave on Oct 08, 2024 1:23pm
I believe you are correct!  They are putting out Cr percentages out of full 68 patients even at 3 years.  Obviously these percentages will go up as more patients reach the time frames!  These are the lowest minimum possible CR rates if all other patients would not be CR at the stated time points.  They are being ultra conservative IMHO.    
Comment by CancerSlayer on Oct 08, 2024 5:52pm
That's how I see it.  Using our interpretation, TR patients (CR + IR = 72.1%) who had a durable response would also be understated....we would have 19 of 63 patients, or 30%.  The NR also states that the TR patients (reported as 19/68 = 27.9%) had a "duration" of this response for at least "450" days.  However, I believe the response duration (90 to 450 days) ...more  
Comment by TommyNickels on Oct 10, 2024 6:09am
I believe the study is designed to report 360 days after the first examination (at 90 days). So 450 days in total. Hopefully the FDA says 75 patients is sufficient.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250